Eli Lilly and Company
As of Oct 22, 2026, Eli Lilly is in Stage 2, the uptrend phase, now in its first week (since Oct 20, 2026). It closed at $1,306.69, at its 52-week high and above its 200-day average, which is rising.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 9 in Drug Manufacturers - General · #1 of 272 in Health Care
Is LLY early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LLY among Drug Manufacturers - General3rd of 21 by relative strength
All 21 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | MRK | Stage 2 · wk 16 | 92 | −0.6% |
| 2 | BIIB | Stage 2 · wk 21 | 92 | +11.6% |
| 3 | LLY | Stage 2 · wk 1 | 90 | +13.5% |
| 4 | AMGN | Stage 2 · wk 16 | 87 | +10.1% |
| 5 | OGN | Stage 2 · wk 23 | 87 | +0.1% |
| 6 | BMY | Stage 3 · wk 1 | 85 | +4.1% |
| 7 | JNJ | Stage 2 · wk 16 | 83 | −0.6% |
| 8 | PFE | Stage 2 · wk 8 | 77 | +7.9% |
Eli Lilly: quick answers
What stage is Eli Lilly in?
As of Oct 22, 2026, Eli Lilly (LLY) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 20, 2026 and is in its first week there. What the four stages mean
Is Eli Lilly in an uptrend?
Yes. Eli Lilly is in a Stage 2 uptrend. It trades 20.8% above its 200-day average, which is rising.
How far is Eli Lilly from its 52-week high?
Eli Lilly closed at $1,306.69 on Oct 22, 2026, at its 52-week high. Its 52-week low is $807.34.
How has Eli Lilly performed over the past year?
As of Oct 22, 2026, Eli Lilly is up 64.5% over the past year and up 21.5% so far in 2026.
Which sector and industry is Eli Lilly in?
Eli Lilly is in the Drug Manufacturers - General industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - General
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company has a strategic partnership with Metis TechBio Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.